Impact of Adjunctive Cilostazol on Microvascular Resistance in Non-ST Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention

Impact of Adjunctive Cilostazol on Microvascular Resistance in Non-ST Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: Prospective Randomization Study : Pilot Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000044

Enrollment

100

Registered

2010-10-11

Start date

2010-10-19

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Case group was medicated with cilostazol 200mg at least 4 hours before percutaneous coronary intervvention and control group was not medicated. The objective of this study is to compare the mi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age >= 18years 2) Patients with Non-ST elevation myocardial infarction who underwent percutaneous coronary intervention within 72hours 3) Single coronary lesion 4) Patients who can medicated with dual antiplatelet drugs, at least 6 months after PCI

Exclusion criteria

Exclusion criteria: 1) ST-elevation myocardial infarction, Unstable angina, Stable angina 2) Cardiogenic shock 3) Renal insufficiency (creatinine >2.0 mg/dl) 4) Life expectancy < 1 year 5) Severe liver dysfunction 6) Pregnancy or immune deficiency 7) Bleeding tendency or coagulopathy

Design outcomes

Primary

Measure	Time frame
The change of Index of microvascular resistance	—

Secondary

Measure	Time frame
All major adverse cardiovascular events ;All major adverse cardiovascular events	—

Countries

Korea, Republic of

Contacts

Public ContactCheol Ung Choi

Koera University Guro Hospital

Outcome results